Health · 5 views
Remibrutinib Cuts Multiple Sclerosis Relapse Rates in Phase III Trials
(MedPage Today) -- Twice daily oral doses of 100 mg of the Bruton's tyrosine kinase (BTK) inhibitor remibrutinib reduced relapses more than teriflunomide (Aubagio) in patients with relapsing multiple sclerosis (MS), data from two…
AI Summary
Twice‑daily oral doses of 100 mg remibrutinib, a Bruton's tyrosine kinase inhibitor, lowered relapse rates more than teriflunomide (Aubagio) in patients with relapsing multiple sclerosis. The finding comes from data collected in two identical phase III trials.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- U.S. measles cases more than double what they were last year as outbreak spreadsContinue reading
- 'The Cat Is Out of the Bag': What We Heard This WeekContinue reading
- Trio of IgA Nephropathy Drugs Proves Mettle in Interim AnalysesContinue reading
- Young adults with cancer report putting off appointments, getting dismissed by doctorsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow